Emergent BioSolutions Inc. — Director's Dealing 2017

Nov 7, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2017-11-03

Reporting Person: Abdun-Nabi Daniel (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-11-03	Common Stock	M	11508	$22.03	Acquired	215642	Direct
2017-11-03	Common Stock	S	11508	$42.50	Disposed	204134	Direct
2017-11-03	Common Stock	M	20000	$14.44	Acquired	224134	Direct
2017-11-03	Common Stock	S	20000	$42.92	Disposed	204134	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-11-03	Stock Option (Right to Buy)	$22.03	M	11508	Disposed	2018-03-14	Common Stock (11508)	Direct
2017-11-03	Stock Option (Right to Buy)	$14.44	M	20000	Disposed	2019-03-12	Common Stock (20000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1000	Indirect

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.47 to $42.78, inclusive.

F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.70 to $43.00, inclusive.

F4: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F5: Consists of an option granted under the company's stock incentive plan as amended and restated.

F6: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.